Quantcast
Home > Quotes > OTIC
OTIC

Otonomy, Inc. Common Stock (OTIC) Quote & Summary Data

$2.75
*  
0.14
4.84%
Get OTIC Alerts
*Delayed - data as of Mar. 22, 2019  -  Find a broker to begin trading OTIC now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
9.5
Today's High / Low
$ 2.93 / $ 2.70
Share Volume
205,247
50 Day Avg. Daily Volume
136,893
Previous Close
$ 2.89
52 Week High / Low
$ 4.85 / $ 1.50
Market Cap
84,384,883
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -1.64
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.58

Intraday Chart

Shares Traded

Share Volume:
205,247
50 Day Avg. Daily Volume:
136,893

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.64

Trading Range

The current last sale of $2.75 is 83.33% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 2.93 $ 4.85
 Low: $ 2.70 $ 1.50

Company Description (as filed with the SEC)

Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. We pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs including Ménière's disease, hearing loss and tinnitus. OTIVIDEX is a steroid in development for the treatment of Ménière's disease. Two Phase 3 trials in Ménière's disease patients were completed in the second half of 2017. The AVERTS-2 trial, conducted in Europe, achieved its primary endpoint (p value = 0.029), while the AVERTS-1 trial, conducted in the United States, did not (p value = 0.62).  ... More ...  



Risk Grade

Where does OTIC fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 2.89
Open Date:
Mar. 22, 2019
Close Price:
$ 2.75
Close Date:
Mar. 22, 2019


Consensus Recommendation

Analyst Info